Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FirstEnergy Corp. (FE) vs Pfizer Inc (PFE) Price & Performance

FirstEnergy Corp.Trade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

FirstEnergy Corp. vs Pfizer Inc — how do they compare? FirstEnergy Corp. trades at $46.86 (market cap $27.06B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 5.7× FirstEnergy Corp.'s market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.

FEPFE
Market Cap
$27.06B$154.18B
Sector
UtilitiesHealth
52-Week High
$51.91$28.56
52-Week Low
$42.83$23.60
Enterprise Value
$55.98B$205.67B
Dividend Yield
3.98%6.36%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FirstEnergy Corp.

FirstEnergy (FE) trades at $47.47, up 0.2% today, with a bearish technical signal from indicators like the 6-day RSI at 11.10 and ADX signaling strong trend strength. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, but revenue growth is supported by data center demand and a $36 billion grid investment plan. Analyst consensus is a Buy with a $52.67 price target, though technicals suggest near-term pressure.

The outlook is mixed: strong fundamentals with rising revenue and stable margins offer long-term value, but technical bearishness and high debt levels pose risks. Investment opportunity lies in grid expansion and data center growth, while risks include execution challenges and interest rate sensitivity. The stock presents a defensive play with growth potential amid volatility.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About FirstEnergy Corp.

FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.

Read more on FE

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE